2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

4021 Belantamab mafodotin, lenalidomide, and dexamethasone (Bela-Rd) overcomes the adverse prognostic impact of high circulating tumor cells in newly diagnosed multiple myeloma

Evangelos Terpos, MD, Ioannis Ntanasis-Stathopoulos, MD2, Charalampos Filippatos3, Panagiotis Malandrakis, MD, MSc, PhD4, Ioannis V Kostopoulos, PhD, MSc5, Ioannis Lagoudis6, Nikolaos Kanellias, MD, PhD7, Magdalini Migkou8, Foteini Theodorakakou, MD9, Vasiliki Spiliopoulou10, Eirini Solia, MD11, Evangelos Eleutherakis-Papaiakovou12, Ilias Katsadouros, MD13, Panagiotis Boutsikos, MD14, Ourania Tsitsilonis, MD,PhD15, Efstathios Kastritis, MD16, Maria Gavriatopoulou, MD17, Meletios-Athanasios (Thanos) C. Dimopoulos, MD18
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 National and Kapodistrian University of Athens, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 National and Kapodistrian University of Athens, Athens, Greece
13 National and Kapodistrian University of Athens, Athens, Greece
14 National and Kapodistrian University of Athens, Athens, Greece
15 National and Kapodistrian University of Athens, Athens, Greece
16 National and Kapodistrian University of Athens, Athens, Greece
17 National and Kapodistrian University of Athens, Athens, Greece
18 National and Kapodistrian University of Athens, Athens, Greece

Introduction: Circulating tumor cells (CTCs) have emerged as a key predictor of survival outcomes in patients with newly diagnosed multiple myeloma (NDMM). Belantamab mafodotin, an anti-BCMA antibody-drug conjugate, combined with lenalidomide and dexamethasone (Bela-Rd), has demonstrated robust safety and efficacy in transplant-ineligible (TI), intermediate-fit, and frail NDMM patients in the phase 1/2 Bela-Rd trial. However, the impact of baseline CTC burden remains unknown.

Methods: We evaluated NDMM patients enrolled in the phase 1/2 Bela-Rd trial (NCT04808037). Baseline peripheral blood samples were analyzed for the quantification of CTCs prior to treatment initiation, utilizing next-generation flow cytometry (NGF). A cutoff of 0.02% was pre-specified per relevant literature in order to stratify patients according to baseline CTC burden. The primary endpoint was progression-free survival (PFS), complemented by overall survival (OS). Secondary endpoints included overall response (ORR, ≥PR), very good partial response or better (≥VGPR) and complete response or better (≥CR) rates.

Results: Among 66 evaluable patients, the median age was 76 years (range, 63–89), with a male predominance (n = 38; 58.5%). 36 patients (54.5%) were stratified into the low CTC cohort (<0.02%) and 30 patients (45.5%) into the high CTC cohort (≥0.02%). Baseline demographic characteristics were well-balanced between the two groups, demonstrating no statistically significant differences in median age (78 vs. 80 years; p = 0.686) or sex distribution (58.8% vs. 60.0% male; p = 1.000). Furthermore, standard laboratory parameters including serum lactate dehydrogenase (p = 0.595), calcium (p = 0.836), platelets (p = 0.118), and creatinine (p = 0.404) were comparable between the low and high CTC cohorts.

However, a significantly greater proportion of high-risk patients was observed in the high CTC cohort (53.3% vs. 20.6% in the low CTC cohort; p = 0.014). Patients in the high CTC cohort presented with a greater baseline tumor burden, reflected by elevated median Beta-2 microglobulin levels (4.2 mg/L vs. 3.1 mg/L; p = 0.004) and more pronounced anemia (median hemoglobin 10.2 g/dL vs. 11.2 g/dL; p = 0.039) compared to the low CTC group.

Treatment with Bela-Rd yielded deep responses, irrespective of baseline CTC burden. The ORR was 98.4%, with 87.5% achieving ≥VGPR, and 59.4% achieving ≥CR. The ORR was 100% in the low CTC group compared to 96.7% in the high CTC group (p = 0.469). Similarly, there were no statistically significant differences in the rates of ≥VGPR (88.2% vs. 86.7%; p = 1.000) or ≥CR (58.8% vs. 60.0%; p = 1.000).

Despite the observed high-risk profile of patients in the high CTC cohort, these individuals did not demonstrate inferior outcomes over a median follow-up of 55.5 months. The 4-year PFS rate between low and high CTC patients was 71.4% vs 66.4%, respectively (p=0.768). The 4-year OS rate was 74.3% and 75.3% between the two groups, respectively (p=0.822). Consequently, no differences were noted in the time-dependent risk of OS (HR=0.86, 95%CI: 0.32-2.32) or PFS (HR= 0.90, 95%CI: 0.37-2.19).

A sensitivity analysis among cytogenetic standard-risk and high-risk patients did not alter the aforementioned observations, as no differences were observed either for the risk of disease progression or death. Finally, an exploratory analysis investigating an alternative optimal threshold for survival curve separation, yielded a cutoff of 0.00026% both for PFS and OS. Despite that, no statistically significant differences were observed either in PFS (p=0.511) or OS (p=0.425).

Conclusion: Our findings demonstrate that frontline therapy with Bela-Rd overcomes the adverse prognostic impact of elevated baseline CTCs in TI, intermediate fit and frail NDMM patients.

Evangelos Terpos, MD: Swixx - Honoraria; Takeda - Honoraria; Menarini - Honoraria; Johnson & Johnson - Honoraria; Sanofi - Honoraria; GSK - Honoraria; Forus - Honoraria; Bristol Myers Squibb - Honoraria; Antengene - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; EUSA Pharma - Honoraria; Johnson & Johnson - Research Funding; GSK - Research Funding; Sanofi - Research Funding; Menarini - Research Funding; Menarini - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)